United Therapeutics Corp

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 3251.22, 3703.15, 4279.72, 5117.28, 6165.5 ], "ebit_estimate": [ 1515.8, 1779.1, 2129.14, 2601.16, 3172.69 ], "ebitda_estimate": [ 1620.87, 1794.25, 2173.52, 3270.73, 3338.45 ], "net_income_estimate": [ 1247.21, 1458.98, 1746.69, 2145.74, 2606.99 ], "per_share_eps_estimate": [ 27.13, 32.33, 38.11, 44.81, 54.02 ], "eps_nri_estimate": [ 27.23, 31.9, 37.21, 44.81, 54.02 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 178.2, 195.13, 272.75, null, null ], "pretax_income_estimate": [ 1601.28, 1872.91, 2242.27, 2731.06, 3307.01 ], "operating_cash_flow_per_share_estimate": [ 34.15, 38.48, 53.06, null, null ], "roa_estimate": [ 15.4, 14.1, 7.9, null, null ], "roe_estimate": [ 17.72, 16.33, 16.09, null, null ], "gross_margin_estimate": [ 87.56, 88.59, 88.67, 89, 88 ], "operating_cash_flow_estimate": [ 1611.72, 1816.41, 2504.43, null, null ], "pettm_estimate": [ 20.17, 16.92, 14.36, 12.21, 10.13 ], "long_term_growth_rate_mean": 10.8, "long_term_revenue_growth_rate_mean": "10.72", "future_per_share_eps_estimate_growth": 11.8, "future_eps_nri_estimate_growth": 10.8, "future_revenue_estimate_growth": 10.72, "future_ebit_estimate_growth": 13.04, "future_ebitda_estimate_growth": 11.2, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 10.12, "future_pretax_income_estimate_growth": 10.11, "future_book_value_per_share_estimate_growth": 17.85, "future_roa_estimate_growth": -21.93, "future_roe_estimate_growth": -6.68, "future_gross_margin_estimate_growth": 0.37, "future_operating_cash_flow_per_share_estimate_growth": 17.14 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 807.68, 822.67, 841.43, 762.43, 781.73, 853.37, 933.57 ], "ebit_estimate": [ 390.78, 395.92, 394.94, 397.1, 407.1, 446.3, 484.43 ], "ebitda_estimate": [ 413.55, 439.83, 412.41, null, null, null, null ], "net_income_estimate": [ 319.86, 324.22, 324.61, 342.87, 350.67, 382, 413.9 ], "per_share_eps_estimate": [ 6.92, 7.03, 6.99, 7.18, 7.32, 7.95, 8.57 ], "eps_nri_estimate": [ 6.95, 7.12, 7.08, 7.18, 7.32, 7.95, 8.57 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 409.87, 414.56, 416.19, 418, 425.5, 477, 529.5 ], "operating_cash_flow_per_share_estimate": [ 7.93, 8.4, 7.53, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 88.03, 87.7, 87.23, null, null, null, null ], "operating_cash_flow_estimate": [ 374.3, 396.48, 355.42, null, null, null, null ], "pettm_estimate": [ 19.46, 19.18, 18.58, 17.63, null, null, null ], "long_term_growth_rate_mean": 10.8, "long_term_revenue_growth_rate_mean": "10.72", "future_per_share_eps_estimate_growth": 11.8, "future_eps_nri_estimate_growth": 10.8, "future_revenue_estimate_growth": 10.72, "future_ebit_estimate_growth": 13.04, "future_ebitda_estimate_growth": 11.2, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 10.12, "future_pretax_income_estimate_growth": 10.11, "future_book_value_per_share_estimate_growth": 17.85, "future_roa_estimate_growth": -21.93, "future_roe_estimate_growth": -6.68, "future_gross_margin_estimate_growth": 0.37, "future_operating_cash_flow_per_share_estimate_growth": 17.14 }